Hepatite B (VHB) e Delta (VHD) em cinco municípios do Estado Maranhão: prevalência e fatores associados

Detalhes bibliográficos
Ano de defesa: 2018
Autor(a) principal: NUNES, Jomar Diogo Costa lattes
Orientador(a): FERREIRA, Adalgisa de Souza Paiva lattes
Banca de defesa: PEREZ, Renata de Mello lattes, BRANCO, Maria dos Remédios Freitas Carvalho lattes, FONSECA, Lena Maria Barros lattes, AZEVEDO, Conceição de Maria Pedrozo e Silva de lattes
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal do Maranhão
Programa de Pós-Graduação: PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE/CCBS
Departamento: DEPARTAMENTO DE EDUCAÇÃO I/CCSO
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: https://tedebc.ufma.br/jspui/handle/tede/2247
Resumo: Introduction. Hepatitis B Virus (HBV) infection can lead to chronic disease. Hepatitis Delta virus (HDV) coinfection may favor an increased risk for liver cirrhosis and hepatocellular carcinoma (HCC) in HBV carriers. HBV infected individuals may present detectable HBV DNA with absence of hepatitis B surface antigen (HBsAg). HBV and HDV infections prevalence rates are heterogeneous in Brazil. The aim of this study was to estimate the prevalence of HBV and HDV infections located in the state of Maranhão in Brazil (Axixá, Morros, Icatu, Humberto de Campos and Urbano Santos). Methods. A total of 3.856 to 4,000 individuals participated of this study. Sample size was obtained by considering a prevalence of 0.5% of HBsAg (according to previous national survey), absolute error of 0.3% and 95% confidence interval. Individuals should be age 1 or older to participate in this study. Questionnaires were applied to identify sociodemographic characteristics and transmission risk factors. Samples of blood were collected and serologies were performed for HBsAg, antiHBc, anti-HBs and anti-HDV markers by enzyme-linked immunosorbent assay (ELISA). Results. A total of 3.984 individuals were screened for HBsAg serological markers. The prevalence of HBsAg was 2.30%. Anti-HBc marker was found in 38.47% of samples, 13.95% and 20.10% presented isolated anti-HBc and anti-HBs respectively. Considering the 3,984 samples, anti-HDV was found in 0.35% individuals (among the 92 HBV carriers, eight presented the anti-HDV marker, corresponding to 8.6%). Among the 561 participants with anti-HBc alone, 223 (39.75%) Conclusion. The prevalence of HBV in the region was considered to be intermediate (more than 2% of carriers). Among those carriers, 8% tested positive for anti-HDV. Thus, prevention measures should be implemented to prevent Infection by these viruses and progression to liver cirrhosis and HCC.